nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.08.2007 | Guidelines

EANM procedure guideline for ³²P phosphate treatment of myeloproliferative diseases

verfasst von: Jan Tennvall, Boudewijn Brans

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

³²P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom ³²P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.

Purpose

The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for ³²P phosphate therapy.

Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: use of³²P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89(7):2319–27.PubMed

Brandt L, Anderson H. Survival and risk of leukaemia in polycythemia vera and essential thrombocythemia treated with oral radiophosphorus. Eur J Haematol 1995;54(1):21–6.PubMedCrossRef

Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41 (2 suppl 3):18–22.CrossRefPubMed

Barbui T. The leukaemia controversy in myeloprolifertive disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41 (2 Suppl 3):15–7.CrossRefPubMed

Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide Study Group. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leukemia Res 2005;29:481–91.CrossRef

Titel: EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases
verfasst von: Jan Tennvall
Boudewijn Brans
Publikationsdatum: 01.08.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0407-4

Springer Medizin

Abstract

Introduction

Purpose

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections

EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases

[18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer

Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours

PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy

Accuracy of 64-slice CT angiography for the detection of functionally relevant coronary stenoses as assessed with myocardial perfusion SPECT